showed a trendp = 0.052
Antiplatelet therapy showed a trend toward more frequent ticagrelor use in the SGLT2 inhibitor group (56% vs. 41%) and reciprocal clopidogrel use in untreated patients (59% vs. 44%; p = 0.052).
Antiplatelet therapy showed a trend toward more frequent ticagrelor use in the SGLT2 inhibitor group (56% vs. 41%) and reciprocal clopidogrel use in untreated patients (59% vs. 44%; p = 0.052).